Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR controlled-delivery drugs

This article was originally published in The Tan Sheet

Executive Summary

SCOLR Pharma plans to develop 24-hour OTC pseudoephedrine decongestant and12-hour OTC combination ibuprofen/pseudoephedrine cough/cold products using the company's controlled delivery technology (CDT) platform, the firm says April 13. All three products are in the preclinical stages of development. The Bellevue, Wash.-based firm recently announced positive results from trials on 12-hour CDT pseudoephedrine and ibuprofen products and intends to submit both for FDA approval this summer (1"The Tan Sheet" April 4, 2005, p. 15)...
Advertisement

Related Content

Extended-Release Pseudoephedrine Trial Results “Positive,” SCOLR Says
Extended-Release Pseudoephedrine Trial Results “Positive,” SCOLR Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS098096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel